Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Neoadjuvant nab-paclitaxel in the treatment of breast cancerA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerTreatment options in non-muscle-invasive bladder cancer after BCG failureTaxanes in the elderly patient with metastatic breast cancerThe role of taxanes in triple-negative breast cancer: literature reviewAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsNeuropathic cancer pain: What we are dealing with? How to manage it?Chemotherapy-induced peripheral neurotoxicity: a critical analysisMicrotubule-binding agents: a dynamic field of cancer therapeutics.A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor ActivityTaxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancerOral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancerPreoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsHigher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patientsSafety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group studynab-Paclitaxel dose and schedule in breast cancerPhase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Reduction in Circulating Tumor Cell Count following Therapy with nab-Paclitaxel plus Carboplatin in a Patient with Leptomeningeal Carcinomatosis from Breast Cancer.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.Current approaches to the management of Her2-negative metastatic breast cancer.Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.Taxanes for the treatment of metastatic breast cancer.Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
P2860
Q26745420-91F0064B-2845-4A51-9A6E-CC8C700840E6Q26748822-F76CA834-8B7A-4B9D-81AC-8A6CF58B0886Q26752846-2328C68E-6D8E-4719-9C70-136213543145Q26775977-D6BAE187-CBA7-4272-9F55-BF5DFCC36751Q26785458-C3CE5257-BA94-4474-B8D1-5495C15B9F18Q26798356-6196E2D9-6774-4FFC-BE90-30BD69799831Q26798674-85B94B0D-6F91-468E-BCFD-AA4D63271D90Q26998945-0B73F4E8-BB12-4D93-9C58-165E5A8D0801Q27010318-9A99D895-2B9A-4A86-ABC4-E6B5E6928B95Q27690249-7836B68E-0417-4EAA-8CA6-6EDE1C19B96DQ28830651-ECB6AA53-F8DB-429C-8E65-ACE1CF9768F9Q30251429-73D4F282-2594-4E96-9259-7DC6676373EAQ33441033-C06D12F5-61C9-4A4E-9B75-4CE4A93E8236Q33633424-E1FD923C-FCF8-4DA6-9027-C7D7E90CE24FQ33738990-B1D51E5A-D700-4851-BD6A-093D73D8951EQ33830562-995B8D43-AD9C-4FC4-A3A8-5250262CE6F4Q33844469-BBAF7D2D-10B0-4CAD-8E4B-4F2C90F753C5Q33887986-3F9F77F3-873D-4460-ACC8-3435A2702A55Q33932401-C4489A76-A305-41A8-A291-C91BE5AD12F2Q34458581-31D448AE-2122-4FD6-B467-ADF7CE0EE551Q34485539-70E68083-9151-4903-8545-2AB458A0C116Q34713757-8C17C2C6-F7E1-4705-82A9-3C6F1C716C69Q34965672-091493AD-FC84-4446-965F-E67B10C5C018Q34996710-9F275DA5-60E5-4BA2-80AD-2D77DC47A5B1Q35051856-1D14E7E1-38FE-4080-A6CE-BD12455ECCCDQ35128729-C41FC290-6B9D-4BD3-A0EC-EB7CC7B0D6B0Q35180940-BA6FBF63-654D-4CEA-B53E-03414A9F02A2Q35185733-9EE40F82-693C-40A1-92E1-46F9BAD99E88Q35507680-085EA0D8-F465-4356-9E1C-FA5AB8F30EBDQ35695168-812BC00C-72D7-4722-A340-5027D1E17520Q35734193-ED373286-2916-4FD5-A2EE-B1658359545DQ35754251-B6F0D336-053A-44D4-9595-BDD09EE1B13AQ35815486-EE546DA3-A2C8-4501-BB3E-3CF3C16F5AC3Q35832704-10CFC033-1C04-4ED1-ACC8-B7727BAF27DCQ35872691-64622740-D2FA-43FF-81C7-2A4C1D697AF0Q36036125-54FC9C3C-9D20-4D3A-86CA-80D0AB1B4174Q36245461-2F8E68B9-B28E-47E1-91F7-D4E29D5E3465Q36326026-C0F15A40-6626-4BAC-B934-6EAC579B07FEQ36364762-F48C6E84-A0AF-4AA2-95A5-B3F691CA049FQ36379813-2D33802E-4F3A-490F-9693-10E83C26A972
P2860
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Significantly longer progressi ...... for metastatic breast cancer.
@en
Significantly longer progressi ...... for metastatic breast cancer.
@nl
type
label
Significantly longer progressi ...... for metastatic breast cancer.
@en
Significantly longer progressi ...... for metastatic breast cancer.
@nl
prefLabel
Significantly longer progressi ...... for metastatic breast cancer.
@en
Significantly longer progressi ...... for metastatic breast cancer.
@nl
P2093
P356
P1476
Significantly longer progressi ...... for metastatic breast cancer.
@en
P2093
Alicia Clawson
Anatoly N Makhson
Dimitry Krasnojon
Georgiy M Manikhas
Sergey Cheporov
William J Gradishar
P304
P356
10.1200/JCO.2008.18.5397
P407
P577
2009-05-26T00:00:00Z